Skip to main content

Departments

Promotion of Science

An important part of the CTGCT is to communicate and disseminate its work to raise awareness. We want patient families, patient organizations, academics and the scientific community to understand the rationale and urgency of research in cancer immunotherapy and rare neurological diseases, and to include their perspectives. This will encourage further research to expand the scientific basis for understanding the underlying causes of diseases, which would further promote the use of advanced therapies.

To this end, we will engage industry/pharmaceutical partners, researchers and clinicians. We will keep them informed and involved in the CTGCT results to promote novel experimental therapies for rare genetic diseases with gene therapy and cancer immunotherapy, which will also support the uptake and exploitation of the project.

We also intend to engage decision makers. We will appeal to policy, regulatory and translation decision makers to demonstrate the impact of rare disease and cancer comorbidities. These comorbidities contribute significantly to the burden of disease, both in patients and for the whole healthcare system. We will engage relevant stakeholders such as patient advocacy groups, healthcare professionals, researchers, and industry representatives to address these challenges in regulatory or policy initiatives, decision-making, policies, and guidelines.

Accessibility(CTRL+F2)
color contrast
text size
highlighting content
zoom in